Table 6.
Characteristic | Incidental PTMC | Overt PTMC | P-value |
---|---|---|---|
n = 90 (25.5%) | n = 263 (74.5%) | ||
Sex | |||
Male | 18 (20.0%) | 71 (27.0%) | 0.187 |
Female | 72 (80.0%) | 192 (73.0%) | |
Age (Y) | |||
≥45 | 46 (51.1%) | 135 (51.3%) | 0.971 |
<45 | 44 (48.9%) | 128 (48.7%) | |
Tumor size (mm) | |||
≤ 5 | 65 (72.2%) | 112 (42.6%) | <0.001 |
>5 | 25 (27.8%) | 151 (57.4%) | |
BRAF mutation* | |||
Absence | 0 (0.0%) | 5 (12.8%) | – |
Presence | 0 (0.0%) | 34 (87.2%) | |
Multifocality | |||
Absence | 64 (71.1%) | 191 (72.6%) | 0.782 |
Presence | 26 (28.9%) | 72 (27.4%) | |
ETE | |||
Absence | 79 (87.8%) | 236 (89.7%) | 0.605 |
Presence | 11 (12.2%) | 27 (10.3%) | |
Vascular invasion | |||
Absence | 87 (96.7%) | 257 (97.7%) | 0.874 |
Presence | 3 (3.3%) | 6 (2.3%) | |
Surgery | |||
Lobectomy+CND | 0 (0.0%) | 78 (29.7%) | <0.001 |
TT+CND | 0 (0.0%) | 170 (64.6%) | |
TT+CND+LND | 0 (0.0%) | 15 (5.7%) | |
Lobectomy or partial thyroidectomy | 90 (100.0%) | 0 (0.0%) | |
Recurrence** | |||
Overall | 11 (12.2%) | 10 (3.8%) | 0.004 |
LNs | 9 (10.0%) | 7 (2.7%) | 0.009 |
Thyroid bed | 5 (5.6%) | 3 (1.1%) | 0.044 |
Lung | 0 (0.0%) | 1 (0.3%) | 0.443 |
PTMC papillary thyroid microcarcinoma; Y, year; ETE, extrathyroidal extension; TT, total thyroidectomy; CND, central neck dissection; LND, lateral neck dissection; LN, lymph node.
BRAF mutation analysis was started in 2017 and it was performed in 39 patients with PTC.
More than one recurrence occurred in some patients. The bold values mean the P <0.05.